董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Justin H. Roberts | 男 | Director | 43 | 未披露 | 未持股 | 2026-04-01 |
| Cooper C. Collins | 男 | Director | 47 | 10.93万美元 | 未持股 | 2026-04-01 |
| Gail K. Naughton | 女 | Director | 70 | 8.73万美元 | 未持股 | 2026-04-01 |
| Tommy G. Thompson | 男 | Chairman of the Board | 84 | 10.48万美元 | 未持股 | 2026-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Marlan D. Walker | 男 | Chief Executive Officer | 51 | 56.11万美元 | 未持股 | 2026-04-01 |
| Joseph Ziegler | 男 | Principal Financial and Accounting Officer | 53 | 12.00万美元 | 未持股 | 2026-04-01 |
董事简历
中英对照 | 中文 | 英文- Justin H. Roberts
-
贾斯汀·罗伯茨是Rubric Capital Management LP的合伙人，自2016年公司成立以来一直担任该职位。他目前担任Mereo BioPharma [纳斯达克股票代码：MREO ]的非执行董事。在加入Rubric之前，他在Point72资产管理公司工作了七年。罗伯茨先生还曾在摩尔资本管理公司ZS联合公司任职，他的职业生涯始于雷曼兄弟的并购业务投资银行家。
Justin H. Roberts is a Partner at Rubric, a role he has held since the formation of the company in 2016. He currently serves as a Non Executive Director of Mereo BioPharma Group plc [NASDAQ: MREO]. Before Rubric, he spent seven years at Point72 Asset Management. Mr. Roberts has also held roles at ZS Associates, Moore Capital Management, and began his career at Lehman Brothers as an investment banker in their M&A practice. - 贾斯汀·罗伯茨是Rubric Capital Management LP的合伙人，自2016年公司成立以来一直担任该职位。他目前担任Mereo BioPharma [纳斯达克股票代码：MREO ]的非执行董事。在加入Rubric之前，他在Point72资产管理公司工作了七年。罗伯茨先生还曾在摩尔资本管理公司ZS联合公司任职，他的职业生涯始于雷曼兄弟的并购业务投资银行家。
- Justin H. Roberts is a Partner at Rubric, a role he has held since the formation of the company in 2016. He currently serves as a Non Executive Director of Mereo BioPharma Group plc [NASDAQ: MREO]. Before Rubric, he spent seven years at Point72 Asset Management. Mr. Roberts has also held roles at ZS Associates, Moore Capital Management, and began his career at Lehman Brothers as an investment banker in their M&A practice.
- Cooper C. Collins
-
Cooper C. Collins，自2012年2月起担任Therapeuticsmd, Inc.公司董事。Collins先生自2015年6月起担任Fortis BioPharma LLC的首席执行官。Collins先生于2013年5月至2014年4月期间担任Pernix Therapeutics Holdings, Inc. 【 NASDAQ：PTX 】或Pernix的首席战略官，于2010年3月至2013年5月期间担任其总裁兼首席执行官，并于2010年3月至2014年2月期间担任董事。Collins先生于2002年加入Pernix的前身Pernix Therapeutics，Inc.，于2007年1月被任命为董事，2007年12月被任命为总裁，2008年6月被任命为首席执行官，担任这三个职务至2010年3月。2005年12月至2007年12月，Collins先生担任Pernix Therapeutics，Inc.业务和产品开发副总裁，并于2003年12月至2005年12月担任其区域经理。Collins先生受雇于美国国家橄榄球联盟特许球队新奥尔良圣徒队的媒体关系部门三年。在获得足球奖学金期间，Collins先生获得了尼古拉斯州立大学的学士学位，后来他在那里获得了工商管理硕士学位。
Cooper C. Collins has served as a director of Therapeuticsmd, Inc.'s Company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma LLC since June 2015. Mr. Collins served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007 and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department. - Cooper C. Collins，自2012年2月起担任Therapeuticsmd, Inc.公司董事。Collins先生自2015年6月起担任Fortis BioPharma LLC的首席执行官。Collins先生于2013年5月至2014年4月期间担任Pernix Therapeutics Holdings, Inc. 【 NASDAQ：PTX 】或Pernix的首席战略官，于2010年3月至2013年5月期间担任其总裁兼首席执行官，并于2010年3月至2014年2月期间担任董事。Collins先生于2002年加入Pernix的前身Pernix Therapeutics，Inc.，于2007年1月被任命为董事，2007年12月被任命为总裁，2008年6月被任命为首席执行官，担任这三个职务至2010年3月。2005年12月至2007年12月，Collins先生担任Pernix Therapeutics，Inc.业务和产品开发副总裁，并于2003年12月至2005年12月担任其区域经理。Collins先生受雇于美国国家橄榄球联盟特许球队新奥尔良圣徒队的媒体关系部门三年。在获得足球奖学金期间，Collins先生获得了尼古拉斯州立大学的学士学位，后来他在那里获得了工商管理硕士学位。
- Cooper C. Collins has served as a director of Therapeuticsmd, Inc.'s Company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma LLC since June 2015. Mr. Collins served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007 and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department.
- Gail K. Naughton
-
Gail K. Naughton，自2020年3月起担任Therapeuticsmd公司的董事。Naughton博士于2017年4月至2021年6月期间担任Histogen的首席科学官和首席业务发展官，该公司是她创立的一家公司，专注于开发基于模拟胚胎条件下生长的细胞的产品的新型解决方案。Naughton博士于2007年6月至2017年4月期间担任Histogen的董事长兼首席执行官。在加入Histogen之前，Naughton博士于2002年3月至2002年10月担任Advanced Tissue Sciences，Inc.（一家以人为基础的组织工程公司）的副主席，于2000年8月至2002年3月担任总裁，于1995年至2000年担任总裁兼首席运营官，并于1991年至1995年担任执行副总裁兼首席运营官。Naughton博士还曾于2002年8月至2011年6月担任圣地亚哥州立大学工商管理学院院长。她花了超过35年的时间广泛研究组织工程工艺，拥有超过150项美国和外国专利，并创立了两家再生医学公司。Naughton博士已将几种组织工程产品推向市场，包括用于严重烧伤的产品（TransCyte）、糖尿病溃疡的皮肤替代品（Dermagraft）、美学皮肤填充剂（Cosmederm/Cosmeplast），以及用于皮肤护理的SkinMedica的TNS和TNS A +产品。Naughton博士在组织工程领域发表了大量文章，并经常发表演讲。2000年，Naughton博士获得知识产权所有者协会颁发的第27届年度国家年度发明家奖，以表彰她在组织工程领域的开创性工作。自1988年以来，Naughton博士一直担任多个上市公司董事会的董事会成员，其中包括2022年8月至2024年4月期间的CEL-SCI公司【 NYSE American：CVM 】和2014年7月至2018年1月期间的Cytori Therapeutics，Inc. 【 NASDAQ：CYTX 】。Naughton博士在圣弗朗西斯学院获得生物学学士学位，在纽约大学医学中心获得组织学硕士学位和血液学博士学位，并在加州大学洛杉矶分校获得硕士学位。
Gail K. Naughton has served as a director of Therapeuticsmd, Inc.'s Company since March 2020. Dr. Naughton has served as the Chief Scientific Officer and Chief Business Development Officer of Histogen, a company she founded that is focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions, since April 2017. Dr. Naughton served as the Chairman and Chief Executive Officer of Histogen from June 2007 until April 2017. Prior to Histogen, Dr. Naughton was the Vice Chairman of Advanced Tissue Sciences, Inc., a human based tissue engineering company, from March 2002 to October 2002, President from August 2000 to March 2002, President and Chief Operating Officer from 1995 to 2000 and Executive Vice President, Chief Operating Officer from 1991 to 1995. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. She has spent over 30 years extensively researching the tissue engineering process, holds over 105 U.S. and foreign patents, and has founded two regenerative medicine companies. Dr. Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast), and SkinMedica's TNS product for skin care. Dr. Naughton has been extensively published and a frequent speaker in the field of tissue engineering. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton previously served as a member of several public company boards of directors since 1988, including Cytori Therapeutics, Inc. [NASDAQ: CYTX] from July 2014 until January 2018 and CEL SCI Corporation [NYSE American: CVM] from August 2022 until April 2024. - Gail K. Naughton，自2020年3月起担任Therapeuticsmd公司的董事。Naughton博士于2017年4月至2021年6月期间担任Histogen的首席科学官和首席业务发展官，该公司是她创立的一家公司，专注于开发基于模拟胚胎条件下生长的细胞的产品的新型解决方案。Naughton博士于2007年6月至2017年4月期间担任Histogen的董事长兼首席执行官。在加入Histogen之前，Naughton博士于2002年3月至2002年10月担任Advanced Tissue Sciences，Inc.（一家以人为基础的组织工程公司）的副主席，于2000年8月至2002年3月担任总裁，于1995年至2000年担任总裁兼首席运营官，并于1991年至1995年担任执行副总裁兼首席运营官。Naughton博士还曾于2002年8月至2011年6月担任圣地亚哥州立大学工商管理学院院长。她花了超过35年的时间广泛研究组织工程工艺，拥有超过150项美国和外国专利，并创立了两家再生医学公司。Naughton博士已将几种组织工程产品推向市场，包括用于严重烧伤的产品（TransCyte）、糖尿病溃疡的皮肤替代品（Dermagraft）、美学皮肤填充剂（Cosmederm/Cosmeplast），以及用于皮肤护理的SkinMedica的TNS和TNS A +产品。Naughton博士在组织工程领域发表了大量文章，并经常发表演讲。2000年，Naughton博士获得知识产权所有者协会颁发的第27届年度国家年度发明家奖，以表彰她在组织工程领域的开创性工作。自1988年以来，Naughton博士一直担任多个上市公司董事会的董事会成员，其中包括2022年8月至2024年4月期间的CEL-SCI公司【 NYSE American：CVM 】和2014年7月至2018年1月期间的Cytori Therapeutics，Inc. 【 NASDAQ：CYTX 】。Naughton博士在圣弗朗西斯学院获得生物学学士学位，在纽约大学医学中心获得组织学硕士学位和血液学博士学位，并在加州大学洛杉矶分校获得硕士学位。
- Gail K. Naughton has served as a director of Therapeuticsmd, Inc.'s Company since March 2020. Dr. Naughton has served as the Chief Scientific Officer and Chief Business Development Officer of Histogen, a company she founded that is focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions, since April 2017. Dr. Naughton served as the Chairman and Chief Executive Officer of Histogen from June 2007 until April 2017. Prior to Histogen, Dr. Naughton was the Vice Chairman of Advanced Tissue Sciences, Inc., a human based tissue engineering company, from March 2002 to October 2002, President from August 2000 to March 2002, President and Chief Operating Officer from 1995 to 2000 and Executive Vice President, Chief Operating Officer from 1991 to 1995. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. She has spent over 30 years extensively researching the tissue engineering process, holds over 105 U.S. and foreign patents, and has founded two regenerative medicine companies. Dr. Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast), and SkinMedica's TNS product for skin care. Dr. Naughton has been extensively published and a frequent speaker in the field of tissue engineering. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton previously served as a member of several public company boards of directors since 1988, including Cytori Therapeutics, Inc. [NASDAQ: CYTX] from July 2014 until January 2018 and CEL SCI Corporation [NYSE American: CVM] from August 2022 until April 2024.
- Tommy G. Thompson
-
Tommy G. Thompson，2020年至2022年任威斯康星大学系统总裁；2001年至2005年任美国卫生与公众服务部部长；1987年至2001年任威斯康星州州长；2005年至2009年任Deloitte & Touche USA LLP高级顾问；2005年至2012年任Akin Gump Strauss Hauer & Feld LLP合伙人；2005年至2011年任Logistics Health，Inc.总裁，2007年至2011年任董事会主席；2013年至与Healthpeak Properties合并之前，曾任Physicians Realty Trust（前纽约证券交易所代码：DOC）董事会主席，Inc.公司于2024年任职；曾任Scilex Holding Company（纳斯达克：SCLX）董事，2022年至2023年任职；Tyme Technologies, Inc.（原纳斯达克：TYME），2018年至2020年任职；曾在其他多个上市公司董事会担任董事，包括C.R. Bard，Inc.（原纽约证券交易所代码：BCR）；Cytori Therapeutics，Inc.（现为Plus Therapeutics，纳斯达克：PSTV）；Cancer Genetics, Inc.（现为Vyant Bio, Inc.，原为纳斯达克：VYNT）；Centene Corporation（纽约证券交易所代码：CNC）。
Tommy G. Thompson has served as a director of Therapeuticsmd, Inc.'s Company since May 2012 and as the Chairman of the Board of Directors since March 2024. He previously served as the Chairman of the Board of Directors from May 2012 until September 2022 and as Executive Chairman of the Board from September 2022 until March 2024. From July 2020 until March 2022, Secretary Thompson served as the Interim President of the University of Wisconsin system. Secretary Thompson also serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. As the Governor of Wisconsin from January 1987 to February 2001, Secretary Thompson was perhaps best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding healthcare access across all segments of society. As the former Secretary of the U.S. Department of Health & Human Services, or HHS, from February 2001 to January 2005, Secretary Thompson served as the nation's leading advocate for the health and welfare of all Americans. Secretary Thompson was a partner in the law firm of Akin Gump Strauss Hauer & Feld LLP, or Akin Gump, from March 2005 to January 2012, when he resigned to run for the United States Senate. Secretary Thompson served as an Independent Chairman of the Deloitte Center for Health Solutions, a healthcare consulting company, from March 2005 to May 2009. At the Deloitte Center for Health Solutions and at Akin Gump, Secretary Thompson built on his efforts at HHS to work toward developing solutions to the healthcare challenges facing American families, businesses, communities, states, and the nation as a whole. Secretary Thompson has also served as the President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions, from February 2005 to January 2011. Secretary Thompson has served as a Senior Fellow for the Bipartisan Policy Center, a non profit organization focused on bipartisan advocacy and policymaking, since July 2013. Secretary Thompson also serves as a member of the board of directors for United Therapeutics Corporation [NASDAQ: UTHR] and Healthpeak Properties, Inc. (f/k/a Physicians Realty Trust) [NYSE: DOC]. Secretary Thompson also served as a member of the boards of directors of Tyme Technologies, Inc. [NASDAQ: TYMI] from August 2017 to February 2020, Centene Corporation [NYSE: CNC] from April 2005 to January 2022 and Scilex Holding Company [NASDAQ: SCLX] from 2022 to 2023, and has historically served on the boards of directors of other public companies. - Tommy G. Thompson，2020年至2022年任威斯康星大学系统总裁；2001年至2005年任美国卫生与公众服务部部长；1987年至2001年任威斯康星州州长；2005年至2009年任Deloitte & Touche USA LLP高级顾问；2005年至2012年任Akin Gump Strauss Hauer & Feld LLP合伙人；2005年至2011年任Logistics Health，Inc.总裁，2007年至2011年任董事会主席；2013年至与Healthpeak Properties合并之前，曾任Physicians Realty Trust（前纽约证券交易所代码：DOC）董事会主席，Inc.公司于2024年任职；曾任Scilex Holding Company（纳斯达克：SCLX）董事，2022年至2023年任职；Tyme Technologies, Inc.（原纳斯达克：TYME），2018年至2020年任职；曾在其他多个上市公司董事会担任董事，包括C.R. Bard，Inc.（原纽约证券交易所代码：BCR）；Cytori Therapeutics，Inc.（现为Plus Therapeutics，纳斯达克：PSTV）；Cancer Genetics, Inc.（现为Vyant Bio, Inc.，原为纳斯达克：VYNT）；Centene Corporation（纽约证券交易所代码：CNC）。
- Tommy G. Thompson has served as a director of Therapeuticsmd, Inc.'s Company since May 2012 and as the Chairman of the Board of Directors since March 2024. He previously served as the Chairman of the Board of Directors from May 2012 until September 2022 and as Executive Chairman of the Board from September 2022 until March 2024. From July 2020 until March 2022, Secretary Thompson served as the Interim President of the University of Wisconsin system. Secretary Thompson also serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. As the Governor of Wisconsin from January 1987 to February 2001, Secretary Thompson was perhaps best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding healthcare access across all segments of society. As the former Secretary of the U.S. Department of Health & Human Services, or HHS, from February 2001 to January 2005, Secretary Thompson served as the nation's leading advocate for the health and welfare of all Americans. Secretary Thompson was a partner in the law firm of Akin Gump Strauss Hauer & Feld LLP, or Akin Gump, from March 2005 to January 2012, when he resigned to run for the United States Senate. Secretary Thompson served as an Independent Chairman of the Deloitte Center for Health Solutions, a healthcare consulting company, from March 2005 to May 2009. At the Deloitte Center for Health Solutions and at Akin Gump, Secretary Thompson built on his efforts at HHS to work toward developing solutions to the healthcare challenges facing American families, businesses, communities, states, and the nation as a whole. Secretary Thompson has also served as the President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions, from February 2005 to January 2011. Secretary Thompson has served as a Senior Fellow for the Bipartisan Policy Center, a non profit organization focused on bipartisan advocacy and policymaking, since July 2013. Secretary Thompson also serves as a member of the board of directors for United Therapeutics Corporation [NASDAQ: UTHR] and Healthpeak Properties, Inc. (f/k/a Physicians Realty Trust) [NYSE: DOC]. Secretary Thompson also served as a member of the boards of directors of Tyme Technologies, Inc. [NASDAQ: TYMI] from August 2017 to February 2020, Centene Corporation [NYSE: CNC] from April 2005 to January 2022 and Scilex Holding Company [NASDAQ: SCLX] from 2022 to 2023, and has historically served on the boards of directors of other public companies.
高管简历
中英对照 | 中文 | 英文- Marlan D. Walker
Marlan D. Walker，自2022年12月起担任Therapeuticsmd, Inc.公司首席执行官。2016年3月起担任Therapeuticsmd, Inc.公司总法律顾问。Walker先生还曾于2018年4月至2019年12月担任首席开发官，并于2013年6月担任Therapeuticsmd, Inc.公司和知识产权法律顾问，直至成为Therapeuticsmd, Inc.总法律顾问。沃克的经验主要集中在生命科学行业各种学科的法律问题和风险管理方面。在TherapeuticsMD任职之前，他的法律业务包括长期投资组合战略和管理、专利准备和起诉、合同谈判和起草、生命周期管理以及Hatch-Waxman事务。法学院毕业后，他于2005年8月在Greenberg Traurig，LLP任职。2009年3月，他转会至Luce Forward Hamilton & Scripps。2011年6月，Walker先生接受了Medicis Pharmaceutical Corp.的内部知识产权顾问职位，该公司于2012年12月被Valeant Pharmaceutical International，Inc.收购。2013年2月，Walker先生接受了Kilpatrick Townsend & Stockton的一个职位，但在2013年6月，他接受了Therapeuticsmd, Inc.公司的一个职位，再次选择搬到公司内部。沃克于2004年毕业于亚利桑那州立大学桑德拉·戴·奥康纳法学院，获得法学博士学位，并于2005年在乔治·华盛顿大学法学院获得知识产权法法学硕士学位。他拥有分子生物学硕士学位和学士学位，均毕业于杨百翰大学。
Marlan D. Walker has served as Chief Executive Officer of Company since December 2022. Previously he served as General Counsel of Therapeuticsmd, Inc.'s Company from March 2016. Mr. Walker previously also served as Chief Development Officer from April 2018 to December 2019 and as Therapeuticsmd, Inc.'s Corporate and Intellectual Property Counsel from June 2013 until he became Therapeuticsmd, Inc.'s General Counsel. Mr. Walker's experience is focused in management of legal issues and risk in the life science industries across a variety of disciplines. His legal practice prior to his time at TherapeuticsMD included long term portfolio strategy and management, patent preparation and prosecution, contract negotiation and drafting, life cycle management, and Hatch Waxman matters. After law school, he took a position at Greenberg Traurig, LLP in August 2005. In March of 2009, he moved to Luce Forward Hamilton & Scripps. Mr. Walker accepted an in house position as Intellectual Property Counsel for Medicis Pharmaceutical Corp. in June 2011, which was acquired by Valeant Pharmaceutical International, Inc. in December 2012. In February 2013, Mr. Walker accepted a position at Kilpatrick Townsend & Stockton, but chose to move in house again in June 2013, when he accepted a position at Therapeuticsmd, Inc.'s Company. Mr. Walker graduated from Arizona State University Sandra Day O'Connor College of Law with his J.D. in 2004, and an L.L.M. in Intellectual Property Law at The George Washington University Law School in 2005. He holds a Master's Degree in Molecular Biology and a B.S. degree, both earned from Brigham Young University.- Marlan D. Walker，自2022年12月起担任Therapeuticsmd, Inc.公司首席执行官。2016年3月起担任Therapeuticsmd, Inc.公司总法律顾问。Walker先生还曾于2018年4月至2019年12月担任首席开发官，并于2013年6月担任Therapeuticsmd, Inc.公司和知识产权法律顾问，直至成为Therapeuticsmd, Inc.总法律顾问。沃克的经验主要集中在生命科学行业各种学科的法律问题和风险管理方面。在TherapeuticsMD任职之前，他的法律业务包括长期投资组合战略和管理、专利准备和起诉、合同谈判和起草、生命周期管理以及Hatch-Waxman事务。法学院毕业后，他于2005年8月在Greenberg Traurig，LLP任职。2009年3月，他转会至Luce Forward Hamilton & Scripps。2011年6月，Walker先生接受了Medicis Pharmaceutical Corp.的内部知识产权顾问职位，该公司于2012年12月被Valeant Pharmaceutical International，Inc.收购。2013年2月，Walker先生接受了Kilpatrick Townsend & Stockton的一个职位，但在2013年6月，他接受了Therapeuticsmd, Inc.公司的一个职位，再次选择搬到公司内部。沃克于2004年毕业于亚利桑那州立大学桑德拉·戴·奥康纳法学院，获得法学博士学位，并于2005年在乔治·华盛顿大学法学院获得知识产权法法学硕士学位。他拥有分子生物学硕士学位和学士学位，均毕业于杨百翰大学。
- Marlan D. Walker has served as Chief Executive Officer of Company since December 2022. Previously he served as General Counsel of Therapeuticsmd, Inc.'s Company from March 2016. Mr. Walker previously also served as Chief Development Officer from April 2018 to December 2019 and as Therapeuticsmd, Inc.'s Corporate and Intellectual Property Counsel from June 2013 until he became Therapeuticsmd, Inc.'s General Counsel. Mr. Walker's experience is focused in management of legal issues and risk in the life science industries across a variety of disciplines. His legal practice prior to his time at TherapeuticsMD included long term portfolio strategy and management, patent preparation and prosecution, contract negotiation and drafting, life cycle management, and Hatch Waxman matters. After law school, he took a position at Greenberg Traurig, LLP in August 2005. In March of 2009, he moved to Luce Forward Hamilton & Scripps. Mr. Walker accepted an in house position as Intellectual Property Counsel for Medicis Pharmaceutical Corp. in June 2011, which was acquired by Valeant Pharmaceutical International, Inc. in December 2012. In February 2013, Mr. Walker accepted a position at Kilpatrick Townsend & Stockton, but chose to move in house again in June 2013, when he accepted a position at Therapeuticsmd, Inc.'s Company. Mr. Walker graduated from Arizona State University Sandra Day O'Connor College of Law with his J.D. in 2004, and an L.L.M. in Intellectual Property Law at The George Washington University Law School in 2005. He holds a Master's Degree in Molecular Biology and a B.S. degree, both earned from Brigham Young University.
- Joseph Ziegler
Joseph Ziegler，自2023年8月起担任Therapeuticsmd，Inc.的首席财务和会计官，并自2022年1月起担任JZ咨询集团的创始人兼首席执行官，该咨询公司主要专注于为中型市场和创业型企业提供零碎CFO和外包会计服务。他此前曾于2021年4月至2021年12月担任DAS Health（一家向医疗保健提供商提供IT服务的私募股权拥有的提供商）的首席财务官，并于2018年11月至2021年2月担任Encompass Onsite（一家端到端物业解决方案提供商）的首席财务官。在加入Encompass之前，他曾在医疗保健行业担任多个CFO职务，包括私募股权支持的专业药房Biomatrix和Novis Pharmaceuticals。Ziegler先生于2021年12月至2024年10月期间担任Progressive Care公司的董事。他在佛罗里达大西洋大学获得了金融学学士学位和工商管理硕士学位。
Joseph Ziegler has served as Principal Financial and Accounting Officer of Company since August 2023 and has served as founder and chief executive officer of JZ Advisory Group, a consulting company largely focused on providing fractional CFO and outsourced accounting services to middle market and entrepreneurial businesses, since January 2022. He previously served as the Chief Financial Officer of DAS Health, a private equity owned provider of IT Services to healthcare providers, from April 2021 to December 2021 and as the Chief Financial Officer of Encompass Onsite, a provider of end to end property solutions, from November 2018 to February 2021. Prior to joining Encompass Onsite, he held multiple roles as a CFO in the healthcare industry, including private equity backed specialty pharmacy Biomatrix and Novis Pharmaceuticals. Mr. Ziegler served as a director of Progressive Care Inc. from December 2021 until December 2024. He earned his B.S. in Finance and an M.B.A. from Florida Atlantic University.- Joseph Ziegler，自2023年8月起担任Therapeuticsmd，Inc.的首席财务和会计官，并自2022年1月起担任JZ咨询集团的创始人兼首席执行官，该咨询公司主要专注于为中型市场和创业型企业提供零碎CFO和外包会计服务。他此前曾于2021年4月至2021年12月担任DAS Health（一家向医疗保健提供商提供IT服务的私募股权拥有的提供商）的首席财务官，并于2018年11月至2021年2月担任Encompass Onsite（一家端到端物业解决方案提供商）的首席财务官。在加入Encompass之前，他曾在医疗保健行业担任多个CFO职务，包括私募股权支持的专业药房Biomatrix和Novis Pharmaceuticals。Ziegler先生于2021年12月至2024年10月期间担任Progressive Care公司的董事。他在佛罗里达大西洋大学获得了金融学学士学位和工商管理硕士学位。
- Joseph Ziegler has served as Principal Financial and Accounting Officer of Company since August 2023 and has served as founder and chief executive officer of JZ Advisory Group, a consulting company largely focused on providing fractional CFO and outsourced accounting services to middle market and entrepreneurial businesses, since January 2022. He previously served as the Chief Financial Officer of DAS Health, a private equity owned provider of IT Services to healthcare providers, from April 2021 to December 2021 and as the Chief Financial Officer of Encompass Onsite, a provider of end to end property solutions, from November 2018 to February 2021. Prior to joining Encompass Onsite, he held multiple roles as a CFO in the healthcare industry, including private equity backed specialty pharmacy Biomatrix and Novis Pharmaceuticals. Mr. Ziegler served as a director of Progressive Care Inc. from December 2021 until December 2024. He earned his B.S. in Finance and an M.B.A. from Florida Atlantic University.